Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice

Pharmaceutical Research

Volumn 14, Issue 10, 1997, Pages 1472-1478

  Braun, Andrea ^a   Kwee, Lia ^b   Labow, Mark A ^b   Alsenz, Jochem ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Animal model (mouse; Antigenicity; Dosage regimen; Immunomodulation; Interferon alpha (IFN ); Protein aggregates; Route of administration

Indexed keywords

PROTEIN; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERFERON TYPE I, RECOMBINANT; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; POLY I-C; SERUM ALBUMIN;

EID: 0030856842     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012193326789     Document Type: Article

References (23)

1. C. R. Kahn and A. S. Rosenthal. Diabetes Care 2:283-295 (1979).
2. J. Tyllström, B. Karlén, and O. Guilbaud. Proceedings of a Workshop: Immunological aspects of human growth hormone, pp. 19-32 (1985).
3. P. Roos, H. R. Fevold, and C. A. Gemzell. Biochimica et biophysica acta 74:525-531 (1963).
4. M. V. Manning, K. Patel, and R. T. Borchardt. Pharm Res 6:903-918 (1989).
5. M. W. Konrad, A. L. Childs, T. C. Merigan, and E. C. Borden. J Clin Immunol 7:365-375 (1987).
6. K. Bendtzen, M. B. Hansen, M. Diamant, C. Ross, and M. Svenson. Journal of Interferon Research, 14:157-158 (1994).
7. R. A. Figlin, and L. M. Itri. Semin Hematol 25:3 Suppl 3, 9-15 (1988).
8. M. M. Payne, and L. Leadbeater. J. Interferon Res. 11:Suppl., S263 (1991).
9. S. Pestka. Archives of Biochemistry and Biophysics 221:1-37 (1983).
10. C. M. Brand and L. Leadbeater. Journal of Interferon Research, 14:201-203 (1994).
11. K. U. Nolte, B. Schwartz, S. Pestka, and P. v. Wussow. Ann Hematol 66:Suppl 2, A103 (1993).
12. A. Palleroni, A. Aglione, M. Labow, M. Brunda, S. Pestka, F. Sinigaglia, G. Garotta, J. Alsenz, and A. Braun. J. Interferon Res. 14:Suppl. 1, S128 (1994).
13. X-Y. Liu, S. Maeda, K. Collier, and S. Pestka. Gene Anal. Techn. 2:83-88 (1985).
14. B. F. Hogan, F. Constantini, and E. Lacy. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1986).
15. A. Braun and J. Alsenz. Pharm. Res. 14:1394-1400 (1997).
16. R. J. Wills, S. Dennis, H. E. Spiegel, D. M. Gibson, and P. I. Nadler. Clin. Pharmacol. Ther. 35:722-727 (1984).
17. M. Kälkner, H. Hagberg, and A. Karlsson Parra. Eur J Haematol 45:233-234 (1990).
18. W. J. Mayet, G. Hess, G. Gerken, S. Rossol, R. Voth, M. Manns, and K. H. Meyer zum Buschenfelde. Hepatology 10:24-28 (1989).
19. A. George, K. E. Shroff, S. Rath, S. N. Ghosh, S. R. Sengupta and R. S. Kamat. Microbiol. Immunol. 33:479-488 (1989).
20. M. Brenan and R. M. Zinkernagel. Infect. Immun. 41:470-475 (1983).
21. W. V. Moore and P. Leppert. J Clin Endocrinol Metab 51:691-697 (1980).
22. C. S. Henney and E. F. Ellis. The New England Journal of Medicine 278:1144-1146 (1968).
23. G. Steineck, H. Strander, and B-E. Carbin. Acta Oncologica 29:155-162 (1990).